Commitments and Contingencies - Additional Information (Details) - USD ($)		1 Months Ended		5 Months Ended	29 Months Ended
	Aug. 01, 2018	Nov. 30, 2019	Oct. 31, 2017	Dec. 31, 2018	Dec. 31, 2020
Loss Contingencies [Line Items]
Contingent liabilities relating to potential future milestone payments					$ 0
Envisia Therapeutics Inc.
Loss Contingencies [Line Items]
Milestone period			15 years
DSM Collaborative Arrangement
Loss Contingencies [Line Items]
Amount paid due to collaboration arrangement	$ 6,000,000.0			$ 3,000,000.0
Amount of to be paid due to collaborative agreement					$ 9,000,000.0
Contingent payments due (up to)	$ 75,000,000
Avizorex
Loss Contingencies [Line Items]
Asset acquisition, consideration transferred		$ 10,200,000
Milestone payments contingent upon the achievement of certain approvals (up to)		$ 69,000,000.0
Envisia
Loss Contingencies [Line Items]
Milestone payments contingent upon the achievement of certain approvals (up to)			$ 45,000,000.0
Upfront cash payment			$ 10,500,000
Common stock, shares issued (in shares)			263,146
Common stock value			$ 14,300,000